OKYO Stock — OKYO Pharma Limited: Cash, EV, Pipeline

What they do

We are a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. The Company is committed to addressing significant unmet medical needs in corneal and anterior segment diseases through innovative science, targeted therapeutic approaches, and a disciplined clinical and regulatory development strategy.

Source: 20-F FY2026 via SEC EDGAR

Share price

$1.43

Market cap

$75.0M

Cash

$4.6M

Enterprise value

$70.4M

Balance sheet

Cash	$4.6M
Debt	$0.0M
Net cash	$4.6M
Enterprise value	$70.4M
Basic shares	52.5M shares
Fully diluted shares	58.4M shares
Fully diluted market cap	$83.5M
Cash per share	$0.09
Quarterly burn	$0.5M
Cash runway	10.2 quarters

Cash figures as of 2025-07-31. Database snapshot: 2026-11-07.

Share structure

Common

52.5M

Pre-funded warrants

0.0M

Options

5.3M

RSUs

0.0M

Warrants

0.6M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

58.4M

Cap table as of 2026-03-31.

Price history

Loading OKYO daily closes…

Loading price history…

Next catalyst

urcosimod · Est. Apr 1, 2027 · half midpoint · guided in 8 wks

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Apr 1, 2027 in 8 wks half midpoint	urcosimod Phase 2b/3 topline data in neuropathic corneal pain	Phase 2b	neuropathic corneal pain	1H 2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

urcosimod

Stage not disclosed · Active

Aliases OK-101

Target CMKLR1 (ChemR23)

Indications

Neuropathic corneal pain (NCP) (Stage not disclosed)
Other corneal and anterior segment indications (Stage not disclosed)

Status note Lead product candidate, described as in the mid stage of development. Initial indications are neuropathic corneal pain (NCP) and other corneal/anterior segment indications. Pre-clinical development and initial animal-model and human studies described as encouraging; company notes significant risks that it may never become a commercially viable product. Trial phase not stated in the excerpts.

OK-201

Stage not disclosed · Active

Indications

not disclosed (Stage not disclosed)

Status note Second product candidate, described as in the early stage of development. Indication, modality and phase not stated in the excerpts.

Per-asset detail extracted from the 20-F filed 2026-07-20. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product;
Lead indication	Neuropathic Corneal Pain
Lead phase	Phase 3
Active trials	0

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Stonepine Capital	862,996	+12,996	0.99%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

OKYO — OKYO Pharma Limited ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Specialist fund holders

Latest news

OKYO — OKYO Pharma Limited